CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

Core Insights - CERo Therapeutics Holdings, Inc. is advancing its market position with the upcoming Phase 1 clinical trial for Acute Myeloid Leukemia (AML) and has secured a manufacturing agreement with the University of California Davis for its product CER-1236, aiming to dose the first patient in the first half of 2025 [1][2] Company Overview - CERo is an innovative immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that integrates characteristics of both innate and adaptive immunity [2] - The company’s Chimeric Engulfment Receptor T cells (CER-T) are designed to enhance the immune response against tumors by employing phagocytic mechanisms, potentially offering broader therapeutic applications than current CAR-T therapies [2] Clinical Development - The manufacturing of CER-1236 is a critical step before patient dosing, and the company is optimistic about progressing this process with UC Davis, a reputable institution in clinical trial manufacturing [2]